Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703468 · ClinicalTrials.gov registry record · Phase 1
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
A Phase 1 study of Seizures, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT01703468: Completed Phase 1 study of Seizures, sponsored by Roxane Laboratories.
NCT01703468 is a Phase 1 study of Seizures that has completed, run by Roxane Laboratories. The registered enrollment target is 59 participants, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01703468, a Phase 1 study of Seizures, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
Primary Outcome
Blood sampling taken during specified time points to determine bioequivalence
Conditions Studied
Interventions
- DRUG Oxcarbazepine
Study Locations (1)
Texas
- Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT01703468 record still lists
NCT01703468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 1 intervention - of which Oxcarbazepine is the first listed.
NCT01703468 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01703468 about?
NCT01703468 is a clinical study titled "Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
What is the current status of trial NCT01703468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-09. Estimated completion is 2009-10.
What conditions does trial NCT01703468 study?
This clinical trial studies the following conditions: Seizures.
What interventions are being tested in trial NCT01703468?
The interventions under investigation include: Oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT01703468?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01703468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01703468's enrollment target sits among peer trials
59 24th of 39 higher than 16 of 39 other Seizures trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BHV-7000 Responsive Neurostimulation System (RNS) Study
ACTIVE NOT RECRUITING · Phase 1
-
Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector
COMPLETED · Phase 1
-
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
COMPLETED · Phase 1
-
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
COMPLETED · Phase 1
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia